Mark G Kris Selected Research

Adenocarcinoma of Lung

1/2023	Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.
1/2023	Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer.
1/2023	Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.
10/2022	Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas.
1/2021	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.
1/2021	Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor.
10/2020	Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance.
1/2020	MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions.
1/2020	Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.
12/2019	Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark G Kris Research Topics

Disease

146	Neoplasms (Cancer) 12/2023 - 02/2002
116	Lung Neoplasms (Lung Cancer) 12/2023 - 03/2003
77	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2023 - 02/2001
63	Adenocarcinoma of Lung 01/2023 - 01/2005
15	Adenocarcinoma 01/2019 - 03/2004
14	Disease Progression 01/2023 - 05/2005
14	Neoplasm Metastasis (Metastasis) 11/2022 - 11/2002
13	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/2018 - 02/2003
11	Brain Neoplasms (Brain Tumor) 01/2022 - 11/2002
9	Nausea 01/2018 - 10/2002
8	Breast Neoplasms (Breast Cancer) 01/2020 - 02/2002
8	Vomiting 10/2017 - 10/2002
7	Fatigue 01/2018 - 05/2005
7	Carcinoma (Carcinomatosis) 06/2014 - 07/2002
7	Bronchiolo-Alveolar Adenocarcinoma (Adenocarcinoma, Bronchiolo Alveolar) 05/2011 - 11/2004
5	Sarcoma (Soft Tissue Sarcoma) 01/2016 - 02/2007
5	Stomatitis 08/2007 - 06/2003
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2019 - 05/2004
4	Edema (Dropsy) 01/2016 - 06/2003
3	Hypersensitivity (Allergy) 01/2021 - 02/2008
3	Carcinogenesis 01/2021 - 04/2004
3	Mesothelioma 01/2020 - 09/2003
3	Mucinous Adenocarcinoma (Mucinous Carcinoma) 01/2019 - 05/2011
3	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 06/2003
3	Thrombocytopenia (Thrombopenia) 10/2018 - 03/2011
3	Neutropenia 10/2018 - 02/2007
3	Exanthema (Rash) 01/2018 - 09/2005
3	Neuroblastoma 02/2015 - 02/2010
3	Peripheral Nervous System Diseases (PNS Diseases) 01/2012 - 05/2007
2	Hemorrhage 01/2022 - 12/2010
2	Malignant Mesothelioma 01/2020 - 04/2007
2	Diarrhea 01/2018 - 09/2005

Drug/Important Bio-Agent (IBA)

65	ErbB Receptors (EGF Receptor)IBA 04/2023 - 06/2003
53	Tyrosine Kinase InhibitorsIBA 12/2023 - 02/2003
41	Gefitinib (Iressa)FDA Link 12/2014 - 06/2003
36	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 01/2005
17	Biomarkers (Surrogate Marker)IBA 12/2023 - 02/2010
14	Proteins (Proteins, Gene)FDA Link 10/2020 - 02/2002
13	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 05/2007
13	Docetaxel (Taxotere)FDA Link 04/2016 - 02/2001
11	Cisplatin (Platino)FDA LinkGeneric 04/2023 - 02/2001
11	Paclitaxel (Taxol)FDA LinkGeneric 12/2021 - 06/2003
11	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2015 - 10/2003
9	osimertinibIBA 04/2023 - 01/2018
9	Carboplatin (JM8)FDA LinkGeneric 12/2021 - 06/2003
9	human ERBB2 proteinIBA 12/2019 - 02/2012
8	Phosphotransferases (Kinase)IBA 01/2021 - 01/2005
7	Immune Checkpoint InhibitorsIBA 11/2023 - 01/2018
7	Pemetrexed (MTA)FDA Link 10/2022 - 10/2005
6	PlatinumIBA 11/2023 - 02/2007
6	AfatinibIBA 01/2021 - 10/2012
5	cabozantinibIBA 09/2023 - 06/2013
5	RNA (Ribonucleic Acid)IBA 01/2021 - 02/2010
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 07/2012
5	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2020 - 01/2016
5	Bevacizumab (Avastin)FDA Link 01/2020 - 12/2010
5	AntiemeticsIBA 01/2020 - 10/2002
5	Anaplastic Lymphoma KinaseIBA 03/2016 - 02/2012
4	atezolizumabIBA 12/2023 - 10/2022
4	CrizotinibIBA 09/2023 - 01/2016
4	Gemcitabine FDA Link 01/2020 - 06/2003
4	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020 - 02/2005
4	Messenger RNA (mRNA)IBA 01/2019 - 05/2004
4	EmeticsIBA 10/2017 - 02/2005
4	Vinorelbine (Navelbine)FDA LinkGeneric 04/2016 - 02/2003
4	10-propargyl-10-deazaaminopterin FDA Link 11/2011 - 05/2006
3	dacomitinibIBA 01/2023 - 12/2014
3	durvalumabIBA 01/2021 - 01/2020
3	Albumin-Bound Paclitaxel FDA Link 01/2020 - 02/2008
3	Cytotoxins (Cytolysins)IBA 01/2020 - 09/2003
3	Temozolomide (Temodar)FDA LinkGeneric 10/2018 - 02/2012
3	Codon (Codons)IBA 03/2015 - 09/2008
3	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 01/2012 - 02/2004
3	Folic Acid AntagonistsIBA 11/2011 - 06/2003
3	Everolimus FDA Link 10/2010 - 08/2007
2	B7-H1 AntigenIBA 11/2023 - 01/2018
2	selpercatinibIBA 09/2023 - 01/2019
2	Protons (Proton)IBA 11/2022 - 01/2021
2	Circulating Tumor DNAIBA 11/2022 - 06/2019
2	trametinibIBA 01/2022 - 01/2021
2	Cell-Free Nucleic AcidsIBA 01/2021 - 01/2021
2	ParaffinIBA 10/2020 - 01/2011
2	Formaldehyde (Formol)FDA Link 10/2020 - 01/2011
2	cyclo(Arg-Pro) (CI 4)IBA 01/2020 - 05/2011
2	Immunoconjugates (Immunoconjugate)IBA 01/2020 - 01/2018
2	Ado-Trastuzumab EmtansineIBA 01/2020 - 01/2018
2	Alanine Transaminase (SGPT)IBA 01/2018 - 01/2016
2	AnthracyclinesIBA 10/2017 - 02/2016
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2017 - 02/2016

Therapy/Procedure

85	Therapeutics 11/2023 - 10/2003
58	Drug Therapy (Chemotherapy) 11/2023 - 02/2001
17	Radiotherapy 01/2023 - 07/2002
11	Adjuvant Chemotherapy 04/2023 - 07/2007
8	Neoadjuvant Therapy 10/2023 - 09/2012
7	Immunotherapy 01/2021 - 09/2004
5	Aftercare (After-Treatment) 01/2021 - 03/2008
3	Precision Medicine 11/2014 - 01/2007
2	Craniospinal Irradiation 11/2022 - 01/2021
2	Metastasectomy 01/2019 - 03/2013
2	Retreatment 01/2018 - 10/2011